Marksans Pharma Receives USFDA Approval for Benzonatate Capsules
Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) announced the final approval of its Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP, 100 mg & 200 mg (Rx) from the US Food and Drug Administration (USFDA).The approved product is bioequivalent and therapeutically equivalent to Tessalon Capsules, 100 mg and 200 mg, manufactured by Pfizer Inc. Benzonatate is a non-narcotic antitussive used to relieve persistent cough associated with bronchitis, pneumonia, or other lung infections.Marksans Pharma Limited, headquartered in Mumbai, India, is engaged in the research, manufacturing, and marketing of generic...